Integra LifeSciences Holdings Corporation (IART)
NASDAQ: IART · Real-Time Price · USD
12.75
-0.08 (-0.62%)
At close: Oct 30, 2026, 4:00 PM EDT
12.50
-0.25 (-1.96%)
After-hours: Oct 30, 2026, 7:30 PM EDT
IART Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,657 | 1,635 | 1,611 | 1,542 | 1,558 | 1,542 | |
Revenue Growth | 0.84% | 1.54% | 4.47% | -1.03% | 0.99% | 12.43% |
Cost of Revenue | 736.95 | 715.83 | 651.41 | 656.84 | 587.36 | 597.81 |
Gross Profit | 919.84 | 919.42 | 959.12 | 884.74 | 970.31 | 944.64 |
Selling, General & Admin | 659.13 | 676.12 | 665.53 | 656.64 | 616.32 | 637.45 |
Research & Development | 81.88 | 82.43 | 97.43 | 104.19 | 101.19 | 93.05 |
Amortization of Goodwill & Intangibles | 15.07 | 14.95 | 14.19 | 12.38 | 13.88 | 14.16 |
Operating Expenses | 756.08 | 773.5 | 777.15 | 773.21 | 731.39 | 744.66 |
Operating Income | 163.76 | 145.92 | 181.98 | 111.53 | 238.92 | 199.98 |
Interest Expense | -92.09 | -86.26 | -70.63 | -51.38 | -49.59 | -50.4 |
Interest & Investment Income | 17.74 | 18.47 | 20.04 | 17.2 | 11.92 | 6.74 |
Currency Exchange Gain (Loss) | 18.04 | -63.44 | 35.23 | -4.4 | 3.3 | - |
Other Non Operating Income (Expenses) | -2.08 | 62.36 | -30.98 | 8.12 | 8.71 | 19.31 |
EBT Excluding Unusual Items | 105.36 | 77.05 | 135.63 | 81.07 | 213.25 | 175.63 |
Merger & Restructuring Charges | -15.77 | -15.81 | -4.95 | - | - | - |
Impairment of Goodwill | - | -511.37 | - | - | - | - |
Gain (Loss) on Sale of Assets | - | - | - | - | 0.64 | 41.8 |
Asset Writedown | - | - | -11.7 | - | - | -2.75 |
Other Unusual Items | -67.28 | -113.38 | -137.22 | - | - | - |
Pretax Income | 22.31 | -563.5 | -18.24 | 81.07 | 213.89 | 214.68 |
Income Tax Expense | 9.3 | -47.03 | -11.29 | 13.33 | 33.34 | 45.6 |
Earnings From Continuing Operations | 13.01 | -516.47 | -6.94 | 67.74 | 180.55 | 169.08 |
Net Income | 13.01 | -516.47 | -6.94 | 67.74 | 180.55 | 169.08 |
Net Income to Common | 13.01 | -516.47 | -6.94 | 67.74 | 180.55 | 169.08 |
Net Income Growth | - | - | - | -62.48% | 6.79% | 26.28% |
Shares Outstanding (Basic) | 77 | 77 | 77 | 80 | 83 | 85 |
Shares Outstanding (Diluted) | 78 | 77 | 77 | 80 | 84 | 85 |
Shares Change | 1.38% | -0.44% | -4.14% | -3.81% | -2.30% | 0.30% |
EPS (Basic) | 0.17 | -6.74 | -0.09 | 0.85 | 2.18 | 2.00 |
EPS (Diluted) | 0.17 | -6.74 | -0.09 | 0.84 | 2.16 | 1.98 |
EPS Growth | - | - | - | -61.11% | 9.09% | 26.11% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 85.78 | -31.05 | 24.96 | 73.09 | 222.13 | 264.41 |
Free Cash Flow Per Share | 1.10 | -0.41 | 0.32 | 0.91 | 2.66 | 3.09 |
Gross Margin | 55.52% | 56.23% | 59.55% | 57.39% | 62.29% | 61.24% |
Operating Margin | 9.88% | 8.92% | 11.30% | 7.23% | 15.34% | 12.96% |
Profit Margin | 0.78% | -31.58% | -0.43% | 4.39% | 11.59% | 10.96% |
Free Cash Flow Margin | 5.18% | -1.90% | 1.55% | 4.74% | 14.26% | 17.14% |
EBITDA | 317.82 | 297.75 | 322.87 | 235.04 | 357.22 | 319.82 |
EBITDA Margin | 19.18% | 18.21% | 20.05% | 15.25% | 22.93% | 20.73% |
D&A For EBITDA | 154.06 | 151.83 | 140.89 | 123.51 | 118.3 | 119.84 |
EBIT | 163.76 | 145.92 | 181.98 | 111.53 | 238.92 | 199.98 |
EBIT Margin | 9.88% | 8.92% | 11.30% | 7.23% | 15.34% | 12.96% |
Effective Tax Rate | 41.67% | - | - | 16.44% | 15.59% | 21.24% |